{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:46Z","timestamp":1787026606709,"version":"build-2736575974"},"reference-count":159,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Psoriatic arthritis (PsA) is a chronic inflammatory disease primarily affecting peripheral and axial joints, with the possible presence of extra-articular manifestations (EAMs), such as psoriasis, uveitis, and inflammatory bowel disease. Recently, the concept of psoriatic disease (PsD) has been proposed to define a systemic condition encompassing, in addition to joints and EAMs, some comorbidities (e.g., metabolic syndrome, type II diabetes, hypertension) that can affect the disease outcome and the achievement of remission. EAMs and comorbidities in PsA share common immunopathogenic pathways linked to the systemic inflammation of this disease; these involve a broad variety of immune cells and cytokines. Currently, various therapeutics are available targeting different cytokines and molecules implicated in the inflammatory response of this condition; however, despite an improvement in the management of PsA, comprehensive disease control is often not achievable. There is, therefore, a big gap to fill especially in terms of comorbidities and EAMs management. In this review, we summarize the clinical aspects of the main comorbidities and EAMs in PsA, and we focus on the immunopathologic features they share with the articular manifestations. Moreover, we discuss the effect of a diverse immunomodulation and the current unmet needs in PsD.<\/jats:p>","DOI":"10.3389\/fmed.2021.737079","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T02:37:36Z","timestamp":1632364656000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk"],"prefix":"10.3389","volume":"8","author":[{"given":"Lucia","family":"Novelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Massimo","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Marando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Curradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/annrheumdis-2018-214689","article-title":"Verna Wright: father of the spondyloarthropathies","volume":"78","author":"Helliwell","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/rheumatology\/keaa062","article-title":"Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis","volume":"59","author":"Pittam","year":"2020","journal-title":"Rheumatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.160861","article-title":"The risk of developing diabetes mellitus in patients with psoriatic arthritis: a cohort study","volume":"44","author":"Eder","year":"2017","journal-title":"J Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2174\/1573397116666201211124815","article-title":"Prevalence of anxiety, depression, sleep disturbance, fibromyalgia, obesity, and gastroesophageal disease in patients with rheumatic diseases","volume":"17","author":"Azarfar","year":"2020","journal-title":"Curr Rheumatol Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3899\/jrheum.130797","article-title":"Depression and anxiety in psoriatic disease: prevalence and associated factors","volume":"41","author":"McDonough","year":"2014","journal-title":"J Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-4632.2010.04600.x","article-title":"Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity","volume":"50","author":"Attia","year":"2011","journal-title":"Int J Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00508-011-0095-8","article-title":"Osteoporosis in psoriatic arthritis: is there any?","volume":"123","author":"Grazio","year":"2011","journal-title":"Wien Klin Wochenschr."},{"key":"B11","first-page":"138","article-title":"Bone mineral density in patients with psoriatic arthritis","volume":"28","author":"Frediani","year":"2001","journal-title":"J Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.reuma.2013.07.006","article-title":"Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital","volume":"10","author":"Busquets","year":"2014","journal-title":"Reumatol Cl"},{"key":"B13","first-page":"210","article-title":"Psoriasis, psoriatic arthritis, or psoriatic disease?","volume":"33","author":"Scarpa","year":"2006","journal-title":"J Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fmed.2018.00062","article-title":"Comorbidities in spondyloarthritis","volume":"5","author":"Molt\u00f3","year":"2018","journal-title":"Front Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.autrev.2018.11.007","article-title":"Amplifying the concept of psoriatic arthritis: the role of autoimmunity in systemic psoriatic disease","volume":"18","author":"Chimenti","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/1744666X.2021.1825941","article-title":"Multimorbidity and comorbidity in psoriatic arthritis\u2014a perspective","volume":"16","author":"Lubrano","year":"2020","journal-title":"Expert Rev Clin Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10067-014-2652-9","article-title":"Extra-articular manifestations in psoriatic arthritis patients","volume":"34","author":"Peluso","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/art.39973","article-title":"The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort Study","volume":"69","author":"Eder","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jdv.12562","article-title":"Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review","volume":"28","author":"Rouzaud","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3899\/jrheum.170146","article-title":"Nail enthesis ultrasound in psoriasis and psoriatic arthritis: a report from the 2016 GRAPPA annual meeting","volume":"44","author":"Cunha","year":"2017","journal-title":"J Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.autrev.2013.08.006","article-title":"The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies","volume":"13","author":"Novelli","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"13554","DOI":"10.1111\/jcmm.15742","article-title":"Overview of the molecular determinants contributing to the expression of psoriasis and psoriatic arthritis phenotypes","volume":"24","author":"Caputo","year":"2020","journal-title":"J Cell Mol Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: classical vs. paradoxical. The Yin-Yang of TNF and type I interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ced.13731","article-title":"Secukinumab-induced paradoxical pustular psoriasis","volume":"44","author":"Dogra","year":"2019","journal-title":"Clin Exp Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"794","DOI":"10.5021\/ad.2017.29.6.794","article-title":"Paradoxical flare of psoriasis after Ustekinumab therapy","volume":"29","author":"Lee","year":"2017","journal-title":"Ann Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors: a review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/1346-8138.15727","article-title":"Psoriasis: recent progress in molecular-targeted therapies","volume":"48","author":"Honma","year":"2021","journal-title":"J Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/rheumatology\/key070","article-title":"The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis","volume":"58","author":"Veale","year":"2019","journal-title":"Rheumatology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J Clin Invest."},{"key":"B38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3748\/wjg.v25.i18.2162","article-title":"Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment","volume":"25","author":"Fragoulis","year":"2019","journal-title":"World J Gastroenterol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/14712598.2019.1652267","article-title":"Inflammatory cytokines: from discoveries to therapies in IBD","volume":"19","author":"Marafini","year":"2019","journal-title":"Expert Opin Biol Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJM200402193500818","article-title":"Etanercept for Crohn's disease","volume":"350","author":"Travers","year":"2004","journal-title":"N Engl J Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/apt.15370","article-title":"Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNF\u03b1 agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease","volume":"50","author":"Korzenik","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.immuni.2015.10.001","article-title":"Gut-busters: IL-17 Ain't afraid of no IL-23","volume":"43","author":"Whibley","year":"2015","journal-title":"Immunity."},{"key":"B46","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.autrev.2015.11.002","article-title":"Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients","volume":"15","author":"Conigliaro","year":"2016","journal-title":"Autoimmun Rev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut."},{"key":"B49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10792-019-01183-9","article-title":"Ocular manifestations of rheumatic diseases","volume":"40","author":"Kemeny-Beke","year":"2020","journal-title":"Int Ophthalmol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3899\/jrheum.150630","article-title":"Uveitis in spondyloarthritis: an overview","volume":"93","author":"Cantini","year":"2015","journal-title":"J Rheumatol Suppl."},{"key":"B51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.12840","article-title":"Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy","volume":"294","author":"Bridgewood","year":"2020","journal-title":"Immunol Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e13572","DOI":"10.1111\/eci.13572","article-title":"Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: an update","volume":"51","author":"Hysa","year":"2021","journal-title":"Eur J Clin Invest."},{"key":"B53","first-page":"68","article-title":"Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy","volume":"36","author":"Lopalco","year":"2018","journal-title":"Clin Exp Rheumatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/09273948.2013.795228","article-title":"Differential diagnosis of beh\u00e7et uveitis","volume":"21","author":"Tugal-Tutkun","year":"2013","journal-title":"Ocul Immunol Inflamm."},{"key":"B55","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.berh.2016.10.007","article-title":"The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis","volume":"30","author":"Murray","year":"2016","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"102152","DOI":"10.1016\/j.msard.2020.102152","article-title":"Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis","volume":"42","author":"Lopalco","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B57","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/art.38873","article-title":"Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis","volume":"67","author":"Robinson","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3109\/09273948.2016.1158283","article-title":"HLA-B27 anterior uveitis: immunology and immunopathology","volume":"24","author":"Wakefield","year":"2016","journal-title":"Ocul Immunol Inflamm."},{"key":"B59","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.berh.2018.08.002","article-title":"Uveitis and spondyloarthropathies","volume":"31","author":"Sharma","year":"2017","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2147\/OPTH.S88647","article-title":"Clinical and visual outcomes of patients with uveitis in the mid-Atlantic United States","volume":"9","author":"Bajwa","year":"2015","journal-title":"Clin Ophthalmol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/BOR.0000000000000619","article-title":"The use of biologics for uveitis associated with spondyloarthritis","volume":"31","author":"Arepalli","year":"2019","journal-title":"Curr Opin Rheumatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","article-title":"Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients","volume":"46","author":"Calvo-R\u00edo","year":"2016","journal-title":"Semin Arthritis Rheum."},{"key":"B63","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/09273948.2014.967779","article-title":"Certolizumab Pegol, a new anti-TNF-\u03b1 in the armamentarium against ocular inflammation","volume":"24","author":"Lloren\u00e7","year":"2016","journal-title":"Ocul Immunol Inflamm."},{"key":"B64","doi-asserted-by":"publisher","first-page":"628","DOI":"10.4103\/0301-4738.194339","article-title":"Roles of interleukin-17 in uveitis","volume":"64","author":"Guedes","year":"2016","journal-title":"Indian J Ophthalmol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/ecco-jcc\/jjz167","article-title":"Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn's disease","volume":"14","author":"Chateau","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e12527","DOI":"10.1111\/dth.12527","article-title":"Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis","volume":"30","author":"Mugheddu","year":"2017","journal-title":"Dermatol Ther."},{"key":"B67","first-page":"2536","article-title":"Evaluation of JAK inhibition with topical tofacitinib in an experimental autoimmune uveitis model (EAU)","volume":"54","author":"Huang","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"122","DOI":"10.18553\/jmcp.2018.17421","article-title":"Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using US administrative claims data","volume":"25","author":"Kaine","year":"2019","journal-title":"J Manag Care Spec Pharm."},{"key":"B69","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/annrheumdis-2018-eular.1403","article-title":"THU0324 disease activity and patient characteristics by comorbidity among psoriatic arthritis (PSA) patients in a us registry","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/acr.23171","article-title":"Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis","volume":"69","author":"Radner","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10067-018-4332-7","article-title":"Role of comorbidities in spondyloarthritis including psoriatic arthritis","volume":"38","author":"Scriffignano","year":"2019","journal-title":"Clin Rheumatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS ONE."},{"key":"B75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"di Minno","year":"2013","journal-title":"Arthritis Care Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/acr.23333","article-title":"Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study","volume":"70","author":"Ballegaard","year":"2018","journal-title":"Arthritis Care Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.immuni.2017.08.009","article-title":"Foundations of immunometabolism and implications for metabolic health and disease","volume":"47","author":"Hotamisligil","year":"2017","journal-title":"Immunity."},{"key":"B78","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/s0021-9150(99)00463-3","article-title":"Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?","volume":"148","author":"Yudkin","year":"2000","journal-title":"Atherosclerosis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.it.2010.03.001","article-title":"Innate immunity and adipose tissue biology","volume":"31","author":"Sch\u00e4ffler","year":"2010","journal-title":"Trends Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","article-title":"Cardiovascular risk profile of patients with psoriatic arthritis compared to controls\u2014the role of inflammation","volume":"47","author":"Tam","year":"2008","journal-title":"Rheumatology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.3390\/ijms21197041","article-title":"The risk of systemic diseases in those with psoriasis and psoriatic arthritis: from mechanisms to clinic","volume":"21","author":"Woo","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00296-016-3487-2","article-title":"Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms","volume":"37","author":"Yim","year":"2017","journal-title":"Rheumatol Int."},{"key":"B83","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u201cpsoriatic march\u201d: a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s10067-007-0539-8","article-title":"Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis","volume":"26","author":"Tam","year":"2007","journal-title":"Clin Rheumatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/07853890.2013.874661","article-title":"Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-\u03b1 blockers: a meta-analysis of prospective studies","volume":"46","author":"Di Minno","year":"2014","journal-title":"Ann Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.40366","article-title":"Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease","volume":"70","author":"Eder","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.3389\/fimmu.2019.03096","article-title":"IL-17A in psoriasis and beyond: cardiovascular and metabolic implications","volume":"10","author":"von Stebut","year":"2020","journal-title":"Front Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/eurheartj\/ehs263","article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction","volume":"34","author":"Simon","year":"2013","journal-title":"Eur Heart J."},{"key":"B90","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40744-020-00206-7","article-title":"Psoriatic arthritis and diabetes mellitus: a narrative review","volume":"7","author":"Dal Bello","year":"2020","journal-title":"Rheumatol Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11154-016-9381-0","article-title":"Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations","volume":"17","author":"Wolk","year":"2016","journal-title":"Rev Endocr Metab Disord."},{"key":"B92","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jdermsci.2009.02.009","article-title":"Serum high molecular weight adiponectin levels are decreased in psoriasis patients","volume":"55","author":"Shibata","year":"2009","journal-title":"J Dermatol Sci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1038\/ncomms5602","article-title":"HGK\/MAP4K4 deficiency induces TRAF2 stabilization and Th17 differentiation leading to insulin resistance","volume":"5","author":"Chuang","year":"2014","journal-title":"Nat Commun."},{"key":"B94","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/1346-8138.15293","article-title":"Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers","volume":"47","author":"Mazzilli","year":"2020","journal-title":"J Dermatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2010.08.002","article-title":"Concepts of evolutionary medicine and energy regulation contribute to the etiology of systemic chronic inflammatory diseases","volume":"25","author":"Straub","year":"2011","journal-title":"Brain Behav Immun."},{"key":"B96","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tem.2017.11.001","article-title":"JAK\/STAT\u2014emerging players in metabolism","volume":"29","author":"Dodington","year":"2018","journal-title":"Trends Endocrinol Metab."},{"key":"B97","doi-asserted-by":"publisher","first-page":"29301","DOI":"10.1074\/jbc.M115.670331","article-title":"Role of Janus Kinase 3 in predisposition to obesity-associated metabolic syndrome","volume":"290","author":"Mishra","year":"2015","journal-title":"J Biol Chem."},{"key":"B98","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.cmet.2012.11.005","article-title":"Tyk2 and Stat3 regulate brown adipose tissue differentiation and obesity","volume":"16","author":"Derecka","year":"2012","journal-title":"Cell Metab."},{"key":"B99","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ncb3075","article-title":"White-to-brown metabolic conversion of human adipocytes by JAK inhibition","volume":"17","author":"Moisan","year":"2015","journal-title":"Nat Cell Biol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"172940","DOI":"10.1016\/j.ejphar.2020.172940","article-title":"JAK-STAT-dependent regulation of scavenger receptors in LPS-activated murine macrophages","volume":"871","author":"Hashimoto","year":"2020","journal-title":"Eur J Pharmacol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1161\/ATVBAHA.109.193896","article-title":"Jak\/STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells","volume":"30","author":"Manea","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11926-018-0752-2","article-title":"Cardiovascular safety of biologics and JAK inhibitors in patients with rheumatoid arthritis","volume":"20","author":"Kang","year":"2018","journal-title":"Curr Rheumatol Rep."},{"key":"B103","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B104","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbrc.2017.06.020","article-title":"Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice","volume":"490","author":"Wang","year":"2017","journal-title":"Biochem Biophys Res Commun."},{"key":"B105","unstructured":"Charles-SchoemanC\n            SornasseT\n            SokoloveJ\n          Treatment With Upadacitinib Is Associated With Improvements in Reverse Cholesterol Transport in Patients With Rheumatoid Arthritis: Correlation With Changes in Inflammation and HDL Levels\u2014ACR Meeting Abstracts"},{"key":"B106","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40264-020-00958-9","article-title":"Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO VigiBase","volume":"43","author":"Vallejo-Yag\u00fce","year":"2020","journal-title":"Drug Saf."},{"key":"B107","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/phar.2472","article-title":"Risk of venous thromboembolism associated with tofacitinib and baricitinib: a systematic review and indirect meta-analysis","volume":"40","author":"Gim\u00e9nez","year":"2020","journal-title":"Pharmacotherapy."},{"key":"B109","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.it.2018.04.010","article-title":"Immune factors in deep vein thrombosis initiation","volume":"39","author":"Budnik","year":"2018","journal-title":"Trends Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.3390\/ijms22052449","article-title":"Thromboembolic adverse drug reactions in Janus Kinase (JAK) inhibitors: does the inhibitor specificity play a role?","volume":"22","author":"Kotyla","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis","volume":"4","author":"Masciulli","year":"2020","journal-title":"Blood Adv."},{"key":"B112","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities associated with psoriatic arthritis: review and update","volume":"214","author":"Perez-Chada","year":"2020","journal-title":"Clin Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3899\/jrheum.120240","article-title":"Osteoporosis and psoriatic arthritis","volume":"89","author":"Del Puente","year":"2012","journal-title":"J Rheumatol Suppl."},{"key":"B116","doi-asserted-by":"publisher","first-page":"R16","DOI":"10.1186\/ar3240","article-title":"Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis","volume":"13","author":"Pedreira","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.2741\/4600","article-title":"Osteoimmunology: The Nexus between bone and immune system","volume":"23","author":"Dar","year":"2018","journal-title":"Front Biosci."},{"key":"B118","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3389\/fimmu.2018.00657","article-title":"Immunoporosis: immunology of osteoporosis-role of t cells","volume":"9","author":"Srivastava","year":"2018","journal-title":"Front Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000431091","article-title":"Immunology of osteoporosis: a mini-review","volume":"62","author":"Pietschmann","year":"2016","journal-title":"Gerontology."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","article-title":"The interleukin-23\/Interleukin-17 axis links adaptive and innate immunity in psoriasis","volume":"9","author":"Sch\u00f6n","year":"2018","journal-title":"Front Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"479","DOI":"10.5483\/bmbrep.2013.46.10.141","article-title":"The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases","volume":"46","author":"Lee","year":"2013","journal-title":"BMB Rep."},{"key":"B122","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000471798","article-title":"New interleukins in psoriasis and psoriatic arthritis patients: the possible roles of interleukin-33 to interleukin-38 in disease activities and bone erosions","volume":"233","author":"Li","year":"2017","journal-title":"Dermatol Basel."},{"key":"B123","doi-asserted-by":"publisher","first-page":"604055","DOI":"10.3389\/fimmu.2020.604055","article-title":"IL-33\/Vitamin D crosstalk in psoriasis-associated osteoporosis","volume":"11","author":"De Martinis","year":"2021","journal-title":"Front Immunol."},{"key":"B124","first-page":"502","article-title":"The effect of biologic agents on bone homeostasis in chronic inflammatory rheumatic diseases","volume":"37","author":"Di Munno","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"e000065","DOI":"10.1136\/rmdopen-2015-000065","article-title":"Bone and TNF in rheumatoid arthritis: clinical implications","volume":"1","author":"Manara","year":"2015","journal-title":"RMD Open."},{"key":"B126","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/1471-2474-15-289","article-title":"Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era","volume":"15","author":"Haugeberg","year":"2014","journal-title":"BMC Musculoskelet Disord."},{"key":"B127","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/BOR.0b013e328356d212","article-title":"Effects of anti-tumor necrosis factor \u03b1 agents on bone","volume":"24","author":"Kawai","year":"2012","journal-title":"Curr Opin Rheumatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bone.2018.01.027","article-title":"Efficacy of anti-IL-23 monotherapy versus combination therapy with anti-IL-17 in estrogen deficiency induced bone loss conditions","volume":"110","author":"Shukla","year":"2018","journal-title":"Bone."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/jbmr.2228","article-title":"Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-\u03b1 antibodies","volume":"29","author":"Tyagi","year":"2014","journal-title":"J Bone Miner Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s12276-020-0445-6","article-title":"The JAK1\/STAT3\/SOCS3 axis in bone development, physiology, and pathology","volume":"52","author":"Sims","year":"2020","journal-title":"Exp Mol Med."},{"key":"B131","doi-asserted-by":"publisher","first-page":"e0181126","DOI":"10.1371\/journal.pone.0181126","article-title":"A Jak1\/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro","volume":"12","author":"Murakami","year":"2017","journal-title":"PLoS ONE."},{"key":"B132","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.3390\/ijms21239004","article-title":"JAK\/STAT activation: a general mechanism for bone development, homeostasis, and regeneration","volume":"21","author":"Damerau","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00198-021-05871-0","article-title":"Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis","volume":"32","author":"Hamar","year":"2021","journal-title":"Osteoporos Int J."},{"key":"B134","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/ijms21030865","article-title":"Impact of Janus Kinase inhibition with tofacitinib on fundamental processes of bone healing","volume":"21","author":"Gaber","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B135","doi-asserted-by":"publisher","first-page":"eaay4447","DOI":"10.1126\/scitranslmed.aay4447","article-title":"JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function","volume":"12","author":"Adam","year":"2020","journal-title":"Sci Transl Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/1756-185X.13553","article-title":"Systematic review of depression and anxiety in psoriatic arthritis","volume":"22","author":"Kamalaraj","year":"2019","journal-title":"Int J Rheum Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","article-title":"Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study","volume":"76","author":"Michelsen","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B139","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neuron.2020.06.002","article-title":"The bidirectional relationship of depression and inflammation: double trouble","volume":"107","author":"Beurel","year":"2020","journal-title":"Neuron."},{"key":"B140","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12640-016-9696-3","article-title":"Early-life social isolation-induced depressive-like behavior in rats results in microglial activation and neuronal histone methylation that are mitigated by minocycline","volume":"31","author":"Wang","year":"2017","journal-title":"Neurotox Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/acps.13016","article-title":"Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials","volume":"139","author":"K\u00f6hler-Forsberg","year":"2019","journal-title":"Acta Psychiatr Scand."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/j.1468-3083.2011.04308.x","article-title":"Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens","volume":"26","author":"Gniadecki","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"72","DOI":"10.25251\/skin.3.2.39","article-title":"Review of suicide and depression in psoriasis and management of suicide warnings in patients treated with psoriasis drugs","volume":"3","author":"Lebowitz","year":"2019","journal-title":"SKIN J Cutan Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/1756-185X.14029","article-title":"Fibromyalgia and psoriatic arthritis: partners together","volume":"24","author":"Littlejohn","year":"2021","journal-title":"Int J Rheum Dis."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/rheumatology\/kez505","article-title":"Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis","volume":"59","author":"Iannone","year":"2020","journal-title":"Rheumatology."},{"key":"B146","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/1756-185X.13963","article-title":"Fibromyalgia in patients with psoriatic arthritis: relationship with enthesopathy, sleep, fatigue and quality of life","volume":"24","author":"Ulutatar","year":"2021","journal-title":"Int J Rheum Dis."},{"key":"B147","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/1756-185X.13987","article-title":"Fibromyalgia in patients with psoriatic arthritis: impact on disease activity indices, fatigue and health-related quality of life","volume":"24","author":"Elsawy","year":"2021","journal-title":"Int J Rheum Dis."},{"key":"B148","first-page":"2262","article-title":"Outcome measures in psoriatic arthritis","volume":"32","author":"Gladman","year":"2005","journal-title":"J Rheumatol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3899\/jrheum.160924","article-title":"The 12-item psoriatic arthritis impact of disease questionnaire: construct validity, reliability, and interpretability in a clinical setting","volume":"44","author":"Di Carlo","year":"2017","journal-title":"J Rheumatol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00296-019-04251-6","article-title":"Role of inflammation in the pathogenesis and treatment of fibromyalgia","volume":"39","author":"Coskun Benlidayi","year":"2019","journal-title":"Rheumatol Int."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1007\/s00296-018-4138-6","article-title":"Fibromyalgia as a challenge for patients and physicians","volume":"38","author":"Coskun Benlidayi","year":"2018","journal-title":"Rheumatol Int."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.3390\/jcm9061814","article-title":"Gene expression profiling in fibromyalgia indicates an autoimmune origin of the disease and opens new avenues for targeted therapy","volume":"9","author":"Dolcino","year":"2020","journal-title":"J Clin Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.imlet.2014.01.009","article-title":"Fibromyalgia and cytokines","volume":"161","author":"Rodriguez-Pint\u00f3","year":"2014","journal-title":"Immunol Lett."},{"key":"B154","doi-asserted-by":"publisher","first-page":"8564215","DOI":"10.1155\/2018\/8564215","article-title":"Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets-a focus on the JAK-STAT pathway","volume":"2018","author":"Salaffi","year":"2018","journal-title":"Pain Res Manag."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B156","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/ALN.0000000000002130","article-title":"Neuroinflammation and central sensitization in chronic and widespread pain","volume":"129","author":"Ji","year":"2018","journal-title":"Anesthesiology."},{"key":"B157","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clim.2016.09.014","article-title":"Role of the JAK\/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases","volume":"189","author":"Yan","year":"2018","journal-title":"Clin Immunol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"e22925","DOI":"10.4161\/jkst.22925","article-title":"The role of JAK-STAT signaling within the CNS","volume":"2","author":"Nicolas","year":"2013","journal-title":"JAK-STAT."},{"key":"B159","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1093\/rheumatology\/keaa770","article-title":"Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY","volume":"60","author":"Strand","year":"2020","journal-title":"Rheumatology."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.737079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T02:37:47Z","timestamp":1632364667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.737079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":159,"alternative-id":["10.3389\/fmed.2021.737079"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.737079","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"article-number":"737079"}}